The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity - PubMed (original) (raw)
Review
The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity
Richard Baer et al. Curr Opin Genet Dev. 2002 Feb.
Abstract
Although the protein product of the BRCA1 tumor suppressor gene has been implicated in a surprisingly diverse array of biological processes, the molecular mechanism by which BRCA1 loss promotes tumor formation remains unclear. Nonetheless, a pivotal advance has been achieved by recent studies that establish BRCA1 and its partner polypeptide BARD1 as enzymatic mediators of protein ubiquitination. The potent ubiquitin E3 ligase activity of the BRCA1/BARD1 heterodimer may be responsible for many of the biological properties attributed to BRCA1, including its ability to suppress tumor formation in normal cells.
Similar articles
- Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex.
Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, Ohta T, Klevit R. Brzovic PS, et al. Proc Natl Acad Sci U S A. 2003 May 13;100(10):5646-51. doi: 10.1073/pnas.0836054100. Epub 2003 May 5. Proc Natl Acad Sci U S A. 2003. PMID: 12732733 Free PMC article. - The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation.
Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, Ogata H, Ohta T. Hashizume R, et al. J Biol Chem. 2001 May 4;276(18):14537-40. doi: 10.1074/jbc.C000881200. Epub 2001 Mar 6. J Biol Chem. 2001. PMID: 11278247 - Structure of a BRCA1-BARD1 heterodimeric RING-RING complex.
Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Brzovic PS, et al. Nat Struct Biol. 2001 Oct;8(10):833-7. doi: 10.1038/nsb1001-833. Nat Struct Biol. 2001. PMID: 11573085 - The BRCA1/BARD1 ubiquitin ligase and its substrates.
Witus SR, Stewart MD, Klevit RE. Witus SR, et al. Biochem J. 2021 Sep 30;478(18):3467-3483. doi: 10.1042/BCJ20200864. Biochem J. 2021. PMID: 34591954 Free PMC article. Review. - Substrates of the BRCA1-dependent ubiquitin ligase.
Starita LM, Parvin JD. Starita LM, et al. Cancer Biol Ther. 2006 Feb;5(2):137-41. doi: 10.4161/cbt.5.2.2479. Epub 2006 Feb 4. Cancer Biol Ther. 2006. PMID: 16479151 Review.
Cited by
- BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
Randall MP, Egolf LE, Vaksman Z, Samanta M, Tsang M, Groff D, Evans JP, Rokita JL, Layeghifard M, Shlien A, Maris JM, Diskin SJ, Bosse KR. Randall MP, et al. J Natl Cancer Inst. 2024 Jan 10;116(1):138-148. doi: 10.1093/jnci/djad182. J Natl Cancer Inst. 2024. PMID: 37688570 Free PMC article. - Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms.
Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Lima ZS, et al. J Hematol Oncol. 2019 Apr 11;12(1):38. doi: 10.1186/s13045-019-0725-6. J Hematol Oncol. 2019. PMID: 30975222 Free PMC article. Review. - Targeting tumor suppressor networks for cancer therapeutics.
Guo XE, Ngo B, Modrek AS, Lee WH. Guo XE, et al. Curr Drug Targets. 2014 Jan;15(1):2-16. doi: 10.2174/1389450114666140106095151. Curr Drug Targets. 2014. PMID: 24387338 Free PMC article. - The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer.
O'Byrne KJ, Barr MP, Gray SG. O'Byrne KJ, et al. Cancers (Basel). 2011 Mar 17;3(1):1426-53. doi: 10.3390/cancers3011426. Cancers (Basel). 2011. PMID: 24212667 Free PMC article. - Mechanism of cytokinesis failure in ovarian cystadenomas with defective BRCA1 and P53 pathways.
Austria T, Marion C, Yu V, Widschwendter M, Hinton DR, Dubeau L. Austria T, et al. Int J Cancer. 2018 Dec 1;143(11):2932-2942. doi: 10.1002/ijc.31659. Epub 2018 Oct 3. Int J Cancer. 2018. PMID: 29978915 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous